Protara Therapeutics, Inc.
TARANasdaq
$4.10
↑ +0.5%Jul 17 close · end-of-day
Price
1Y↑ +30.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$235.9M
Enterprise Value
$100.1M
P/E
—
P/S
—
P/B
1.3
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$63.3M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-34.9%
ROIC
-121.8%
Debt / Equity
—
Net Cash
$135.8M
Return 1Y
+30.6%
Company profile
Protara Therapeutics, Inc. engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the. treatment of lymphatic malformations. It also develops intravenous choline chloride, an. investigational phospholipid substrate replacement therapy.
- CEO
- Jesse Shefferman
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 30
- Headquarters
- New York
- Website
- protaratx.com
Earnings
TARA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.31↑ +6.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$34.4M | -$47.5M | -$67.1M | -$43.6M | -$49.2M | -$64.5M |
| Net income | -$34.0M | -$47.3M | -$66.0M | -$40.4M | -$44.6M | -$57.4M |
| Diluted EPS | — | -$4.21 | -$5.86 | -$3.57 | -$2.17 | -$1.34 |
| Operating cash flow | -$23.4M | -$34.5M | -$26.5M | -$37.6M | -$35.8M | -$56.4M |
| Free cash flow | -$24.3M | -$35.1M | -$26.6M | -$37.6M | -$35.9M | -$56.5M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$10.7M | -$12.3M | -$14.3M | -$14.1M | -$16.6M | -$14.8M | -$19.1M | -$19.6M |
| Net income | -$9.5M | -$11.2M | -$12.8M | -$11.9M | -$15.0M | -$13.3M | -$17.3M | -$17.8M |
| Diluted EPS | -$0.45 | -$0.50 | -$0.25 | -$0.29 | -$0.35 | -$0.31 | -$0.39 | -$0.31 |
| Operating cash flow | -$7.7M | -$8.4M | -$9.3M | -$14.7M | -$12.3M | -$12.5M | -$16.9M | -$21.3M |
| Free cash flow | — | -$8.4M | — | -$14.8M | -$12.3M | -$12.5M | -$17.0M | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
May 31, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.